We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+15.06%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$146M
AUM Growth
+$16.5M
Cap. Flow
+$7.36M
Cap. Flow %
5.05%
Top 10 Hldgs %
90.62%
Holding
26
New
3
Increased
4
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$20.3M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$8.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$6.28M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.9M
5
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.72M

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$6.88M
2
RGLS
Regulus Therapeutics
RGLS
+$5.47M
3
LRMR icon
Larimar Therapeutics
LRMR
+$3.38M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$3.3M
5
XENT
Intersect ENT, Inc
XENT
+$3.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMTX
26
DELISTED
Dimension Therapeutics, Inc
DMTX
– –
-98,297
Closed -$770K
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2016 Portfolio in Review

As of Q2 2016, Foresite Capital Management III held 26 positions worth $146M, up 13% from $129M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Foresite Capital Management III deployed $7.36M of net new capital in Q2 2016, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Intellia Therapeutics: 763,688 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier.

On the sell side, the largest reduction was Wave Life Sciences, an estimated $6.88M trimmed.

  • Foresite Capital Management III's largest Q2 2016 buy was Intellia Therapeutics: 763,688 shares worth $16.3M.
  • Foresite Capital Management III added most to Alder Biopharmaceuticals in Q2 2016, an estimated $8.7M increase.
  • Foresite Capital Management III's biggest Q2 2016 reduction was Wave Life Sciences, cutting an estimated $6.88M.
  • Foresite Capital Management III fully exited Regulus Therapeutics in Q2 2016, selling an estimated $5.47M.
  • Foresite Capital Management III's ten largest holdings make up 91% of its $146M portfolio in Q2 2016.
  • Foresite Capital Management III opened 3 new positions and closed 8 in Q2 2016.
  • Foresite Capital Management III's portfolio value rose 13% quarter-over-quarter to $146M.

Based on Foresite Capital Management III's 13F filing for Q2 2016, filed 12 Aug 2016.